Inspire Pharmaceuticals Discontinues Trials Of Retinal Disease Drug
DURHAM, N.C.--(BUSINESS WIRE)--Jan. 20, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has discontinued two Phase 2 pilot clinical trials of denufosol tetrasodium intravitreal injection (INS37217 Ophthalmic) in patients with macular edema and has no plans to conduct any further studies of denufosol for the treatment of retinal disease.